心房颤动患者卒中后抗凝治疗分析
本研究基于RAF和RAF-NOACs前瞻性研究数据,比较了接受与未接受桥接治疗的心房颤动卒中患者的临床特征和90天结局。结果显示桥接治疗组复合终点事件发生率更高(11.3% vs 5.0%,P=0.0001),多变量分析显示桥接治疗与复合终点(OR 2.3,95%CI 1.4-3.7,P<0.0001)、缺血终点(OR 2.2,95%CI 1.3-3.9,P=0.005)和出血终点(OR 2.4,95%CI 1.2-4.9,P=0.01)独立相关。
要点
- 桥接治疗组90天复合终点事件发生率显著高于非桥接组。
- 桥接治疗与缺血复发和出血转化风险增加独立相关。
- 高龄和脑白质疏松与桥接治疗使用呈负相关。
核心结论
- 接受低分子肝素桥接治疗的心房颤动卒中患者早期缺血复发和出血转化风险高于未桥接患者。
研究设计与样本
- 基于RAF和RAF-NOACs前瞻性研究的观察性分析,纳入1810例启动口服抗凝治疗的心房颤动卒中患者。
主要发现
- 371例(20%)接受全剂量低分子肝素桥接治疗。
- 多变量分析显示桥接治疗与复合终点相关(OR 2.3,95%CI 1.4-3.7,P<0.0001)。
- 桥接治疗与缺血终点相关(OR 2.2,95%CI 1.3-3.9,P=0.005)。
- 桥接治疗与出血终点相关(OR 2.4,95%CI 1.2-4.9,P=0.01)。
临床怎么用
- 对于急性心房颤动卒中患者,启动口服抗凝治疗时需谨慎评估低分子肝素桥接治疗的获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Bridging therapy with low-molecular-weight heparin reportedly leads to a worse outcome for acute cardioembolic stroke patients because of a higher incidence of intracerebral bleeding. However, this practice is common in clinical settings. This observational study aimed to compare (1) the clinical profiles of patients receiving and not receiving bridging therapy, (2) overall group outcomes, and (3) outcomes according to the type of anticoagulant prescribed. Methods- We analyzed data of patients from the prospective RAF and RAF-NOACs studies. The primary outcome was defined as the composite of ischemic stroke, transient ischemic attack, systemic embolism, symptomatic cerebral bleeding, and major extracerebral bleeding observed at 90 days after the acute stroke. Results- Of 1810 patients who initiated oral anticoagulant therapy, 371 (20%) underwent bridging therapy with full-dose low-molecular-weight heparin. Older age and the presence of leukoaraiosis were inversely correlated with the use of bridging therapy. Forty-two bridged patients (11.3%) reached the combined outcome versus 72 (5.0%) of the nonbridged patients (P=0.0001). At multivariable analysis, bridging therapy was associated with the composite end point (odds ratio, 2.3; 95% CI, 1.4-3.7; P<0.0001), as well as ischemic (odds ratio, 2.2; 95% CI, 1.3-3.9; P=0.005) and hemorrhagic (odds ratio, 2.4; 95% CI, 1.2-4.9; P=0.01) end points separately. Conclusions- Our findings suggest that patients receiving low-molecular-weight heparin have a higher risk of early ischemic recurrence and hemorrhagic transformation compared with nonbridged patients.
引用
- Altavilla R, Caso V, Bandini F, et al. Anticoagulation After Stroke in Patients With Atrial Fibrillation. Stroke. 2019. PMID: 31221054. doi:10.1161/STROKEAHA.118.022856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。